The age of the GSKHPV vaccine has been approved for the age of the subjects who have been vaccinated to 45

cervical cancer is a disease caused by a persistent infection of the high-risk human papillomavirus (HPV) in the female reproductive tractAmong malignant tumors in the female reproductive system in China, cervical cancer has the highest incidence and mortality rate, with about 100,000 new cases and about 30,000 deaths each yeartoday, GlaxoSmithKline (GSK) announced that the age of the HPV vaccine has been approved to 45 years after the technical review of the NationalMedicines(Supervisory Authority's Drug Review Centre)HPV16 and HPV18 are the most common high-risk HPV types in cervical cancerIn China, more than 84.5% of cervical squamous cancer cases are associated with these two high-risk HPV persistent infectionsThe first peak for women at high risk of HPV infection in China is 15 to 24 years old, and the second peak is 40 to 44 years oldthe cervical cancer screening program, the HPV vaccine in the vast majority of women of school age will significantly reduce the incidence of cervical cancer and precancerous lesions, thereby reducing the burden of diseaseHeriot's contains antigens for HPV16 and 18, using asa04patented(adjudonic system) that effectively activates the immune system and produces a long-lasting and effective immune responseat the same time, because of its excellent cross-protection effect on other high-risk HPV, the overall protection effect of Shirec on pre-cervical cancer lesions (CIN3-plus) caused by any high-risk HPV reached 93.2% in the uninfected population